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Objectives. In the present study, the ability of magnolol, a hydroxylated biphenyl compound isolated from Magnolia oﬃcinalis,t o
stimulate osteoblast function and inhibit the release of bone-resorbing mediators was investigated in osteoblastic MC3T3-E1 cells.
Methods. Osteoblast function was measured by cell growth, alkaline phosphatase activity, collagen synthesis, and mineralization.
Glutathione content was also measured in the cells. Bone-resorbing cytokines, receptor activator of nuclear factor-κB ligand
(RANKL), TNF-α, and IL-6 were measured with an enzyme immunoassay system. Results. Magnolol caused a signiﬁcant elevation
of cell growth, alkaline phosphatase activity, collagen synthesis, mineralization, and glutathione content in the cells (P<0.05).
Skeletal turnover is orchestrated by a complex network of regulatory factors. Among cytokines, RANKL, TNF-α,a n dI L - 6w e r e
found to be key osteoclastogenetic molecules produced by osteoblasts. Magnolol signiﬁcantly (P<0.05) decreased the production
of osteoclast diﬀerentiation inducing factors such as RANKL, TNF-α, and IL-6 in the presence of antimycin A, which inhibits
mitochondrial electron transport and has been used as an ROS generator. Conclusion. Magnolol might be a candidate as an agent
for the prevention of bone disorders such as osteoporosis.
1.Introduction
Bonetissueiscontinuouslyreplacedthroughboneformation
by osteoblasts and bone resorption by osteoclasts [1].
Both systemic factors and factors produced in the bone
microenvironment are involved in the complex network
regulating bone metabolism. Some of the locally produced
factors involved in prevention of imbalances between bone
formation and bone resorption also play prominent roles in
diseases characterized by inﬂammation and increased bone
resorption activity. TNF-α and IL-6 are proinﬂammatory
cytokines produced by osteoblasts/stromal cells and well-
known stimulator of bone resorption [2]. As a result,
the number of osteoclasts is increased, leading to bone
resorption, and osteoblast activity is repressed, leading
to decreased mineralization. Receptor activator of nuclear
factor-κBligand(RANKL)isamemberofthetumornecrosis
factor superfamily that is expressed in osteoblasts. RANKL,
secreted mainly by osteoblastic stromal cells, is necessary
for osteoclast formation from its committed precursors,
which bear its receptor RANK. Activation of RANK leads to
activation of downstream signaling pathways including NF-
κB, p38 kinase, and c-Jun N-terminal kinase (JNK) [3]. The
RANKL: RANK signaling pathway could be a major target of
antiresorptive agents.
Magnolia oﬃcinalis (Magnoliaceae) has long been used
for the treatment of fever, headache, anxiety, diarrhea, asth-
ma, and stroke and possesses potent anti-inﬂammatory
eﬀects [4]. It has been reported that magnolol, a com-
pound puriﬁed from Magnolia oﬃcinalis, relaxes rat vascular
smooth muscle [5], scavenges hydroxyl radicals [6], inhibits
neutrophil aggregation and superoxide anion generation
[7, 8], suppresses the expression of vascular cell adhesion
molecule-1 in endothelial cells [9], and inhibits nitric oxide
(NO) production in lipopolysaccharide- (LPS-) activated
macrophages [10]. Previous studies showed that magnolol
could attenuate peroxidative damage and improve the sur-
vival of rats after surgically induced sepsis [11] or sepsis-
induced haemorrhagic shock [12]. Since magnolol has been
reported to have antioxidant eﬀect [13], it seems to have2 Mediators of Inﬂammation
an eﬀect on age-related osteoporosis. In the previous study,
it was demonstrated that apocynin, a naturally occurring
methoxy-substituted catechol, caused a signiﬁcant elevation
of osteoblast diﬀerentiation and decreased the production
of ROS and osteoclast diﬀerentiation inducing factors in
MC3T3-E1 cells [14].
The preosteoblastic MC3T3-E1 cell undergoes a tem-
poral pattern of osteoblast development similar to in vivo
bone formation. Thus, this cell is a well-accepted model of
osteogenesis in vitro [15]. During the proliferative phase,
this cell undergoes DNA synthesis and cell division, resulting
in a rapid increase in cell number until conﬂuence. At this
juncture, proliferation is arrested, and there is an increase
in the sequential expression of mature osteoblastic charac-
teristics including alkaline phosphatase (ALP) production,
conversion of procollagen to collagen, and the deposition of
extracellular matrix on the substrate, which is subsequently
mineralized [16]. In this study, to clarify the role of magnolol
inboneformationandgrowth,theeﬀectsofmagnololonthe
proliferationanddiﬀerentiationofosteoblasticcelllineswere
investigated using MC3T3-E1 in vitro. We also investigated
whether magnolol inhibits the induction of bone resorbing
mediators by antimycin A, which inhibits mitochondrial
electron transport and has been used as an ROS generator.
2. ExperimentalMethods
2.1. Materials. Magnolol isolated from Magnolia oﬃcinalis
was purchased from ChromaDex Inc. (Irvine, CA, USA)
and antimycin A was purchased from Sigma Chemical (St.
Louis, MO, USA). These were dissolved in dimethylsulfoxide
(DMSO) and then diluted with the medium (ﬁnal DMSO
concentration ≤ 0.05% (v/v)). α-Modiﬁed minimal essential
medium (α-MEM) and fetal bovine serum (FBS) were
purchased from Gibco BRL (Grand Island, NY, USA). Other
reagents were of the highest commercial grade available and
purchased from Sigma Chemical (St. Louis, MO, USA).
2.2. Cell Culture. MC3T3-E1 cells (RCB1126, an osteoblast-
like cell line from C57BL/6 mouse calvaria) were obtained
from the RIKEN Cell Bank (Tsukuba, Japan). MC3T3-E1
c e l l sw e r ec u l t u r e da t3 7 ◦Ci n5 %C O 2 atmosphere in
α-modiﬁed minimal essential medium (α-MEM; GIBCO).
Unlessotherwisespeciﬁed,themediumcontained10%heat-
inactivated fetal bovine serum (FBS), 100U/mL penicillin,
and 100mg/mL streptomycin.
2.3. Cell Growth. The cells were suspended in medium and
plated at a density of 104 cells/well into a 24-well culture
dish (Costar, Cambridge, MA, USA). After 48h, the medium
was replaced with serum-free media containing 0.3% bovine
serum albumin supplemented with magnolol. After 2 days
of culture, cell growth was measured by MTT assay. This
assay is based on the ability of viable cells to convert soluble
3-(4,5-dimethyl-thiazol-2yl)-2,5-diphenyl tetrazolium bro-
mide (MTT) into an insoluble dark blue formazan reaction
product. MTT 20μl in 7.2mM phosphate buﬀer solution,
pH 6.5 (5mg/mL), was added to each well, and the plates
were incubated for an additional 2h. After the removal
of solutions in the well, dimethyl sulfoxide was added to
dissolve formazan products, and the plates were shaken for
5min. The absorbance of each well was recorded on a micro-
plate spectrophotometer at 570nm.
2.4. Collagen Content. The cells were treated, at conﬂuence,
with culture medium containing 10mM β-glycerophosphate
and 50μg/mL ascorbic acid (diﬀerentiation medium) to
initiate diﬀerentiation. After 6 days, the cells were incubated
with magnolol for 48h. Collagen content was quantiﬁed
by Sirius Red-based colorimetric assay. Cultured osteoblasts
were washed with PBS, followed by ﬁxation with Bouin’s
ﬂuid for 1h. After ﬁxation, the ﬁxation ﬂuid was removed
and the culture dishes were washed by immersion in running
tap water for 15min. The culture dishes were air dried and
stained by Sirius Red dye reagent for 1h under mild shaking
on a shaker. Thereafter, the solution was removed, and the
cultures were washed with 0.01N HCl to remove nonbound
dye. The stained material was dissolved in 0.1N NaOH, and
absorbance was measured at 550nm.
2.5. Alkaline Phosphatase Activity. The cells were treated, at
conﬂuence, with diﬀerentiation medium to initiate diﬀeren-
tiation. After 6 days, the cells were incubated with magnolol
for 48h. The cells were lysed with 0.2% Triton X-100, with
the lysate centrifuged at 14,000×g for 5min. The clear
supernatant was used to measure the ALP activity, which was
determined using an ALP activity assay kit (Asan Co. Korea).
Protein concentrations were determined using the BioRad
protein assay reagent.
2.6. Calcium Deposition Assay. The cells were treated, at
conﬂuence, with diﬀerentiation medium. After 14 days, the
cells were cultured with medium containing magnolol for 2
days. On harvesting, the cells were ﬁxed with 70% ethanol
for 1h and then stained with 40mM Alizarin Red S for
10min with gentle shaking. To quantify the bound dye, the
stain was solubilized with 10% cetylpyridinium chloride by
shaking for 15min. The absorbance of the solubilized stain
was measured at 561nm.
2.7. Intracellular Glutathione Measurement. The cells were
treated, at conﬂuence, with diﬀerentiation medium to ini-
tiate diﬀerentiation. After 6 days, the cells were incubated
with magnolol for 48h. Cells were lysed by homogenization
in 1-2mL of cold buﬀer containing 50mM MES or phos-
phate (pH 6-7) and 1mM EDTA. After centrifugation at
10,000g for 15min at 4◦C, supernatant was used for assay.
Glutathione was measured by use of the Glutathione Assay
Kit (BioAssay Systems, Hayward, CA, USA) according to
manufacturer’s instructions. Determination of glutathione
is based on the reaction of 5, 5 -dithiobis-2-nitrobenzoic
acid (DTNB) with glutathione which yield a yellow-colored
chromophore, 5-thionitrobenzoic acid (TNB) with a maxi-
mum absorbance at 412nm. Concentrations of glutathione
were determined from a freshly prepared standard curve of
glutathione.Mediators of Inﬂammation 3
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Figure 1: Eﬀect of magnolol on the growth of MC3T3-E1 cells.
Data were expressed as a percentage of control. ∗P<0.05compared
with control.
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Figure 2: Eﬀect of magnolol on the collagen synthesis of MC3T3-
E1 cells. Data were expressed as a percentage of control. The control
value for collagen content was 23.45 ± 0.659μg/106 cells. ∗P<0.05
compared with control.
2.8. Measurement of RANKL, TNF-α, and IL-6. The cells
were treated, at conﬂuence, with diﬀerentiation medium
to initiate diﬀerentiation. After 6 days, the cells were pre-
incubated with magnolol for 1h before treatment with
antimycin A for 48h. RANKL, TNF-α, and IL-6 contents in
the medium were measured with an enzyme immunoassay
system(R&DsystemInc.,Minneapolis,MN,USA)according
to the manufacturer’s recommendation.
2.9. Statistical Analysis. All experiments were carried out in
triplicate, and all results are expressed as mean ± SEM of
at least 3 independent experiments. Statistical signiﬁcance
was determined by analysis of variance and subsequently
applying Dunnett’s t-test (P<0.05).
3. Results
3.1. Eﬀe c to fM a g n o l o lo nt h eG r o w t ha n dD i ﬀerentiation
of MC3T3-E1 Cells. MC3T3-E1 cells were incubated with
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Figure 3: Eﬀect of magnolol on the alkaline phosphatase activity
of MC3T3-E1 cells. Data were expressed as a percentage of control.
The control value for ALP activity was 0.871 ± 0.016 Unit/mg. ∗P<
0.05 compared with control.
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Figure 4: Eﬀect of magnolol on the mineralization of osteoblastic
MC3T3-E1 cells. Data were expressed as a percentage of control.
The control value for mineralization was 0.504 ± 0.006 OD/106
cells. ∗P<0.05 compared with control.
magnolol and cell growth was measured. Cell populations
cultured in basal or magnolol-treated media appeared as
Figure 1. MC3T3-E1 cell growth was promoted by stimula-
tion with magnolol (0.1∼1μM) signiﬁcantly compared with
control cells. The eﬀect of magnolol on collagen synthesis
in osteoblastic MC3T3-E1 cells is shown in Figure 2.T h e
collagen synthesis of MC3T3-E1 cells was signiﬁcantly
increased by the addition of 0.1∼1μM magnolol. ALP
activity was measured to study the eﬀect of magnolol on the
osteoblastic diﬀerentiation in MC3T3-E1 cells. The cultured
cells in the presence of magnolol (0.1 and 1μM) caused
a signiﬁcant increase in the ALP activity of osteoblastic
cells (Figure 3). The MC3T3-E1 cells were treated with
various concentrations of magnolol, and the mineralization
of osteoblasts was measured. The increase of mineralization
was signiﬁcant at magnolol concentrations of 0.1 and 1μM
in MC3T3-E1 cell culture (Figure 4).4 Mediators of Inﬂammation
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Figure 5: Eﬀect of magnolol on the glutathione content of MC3T3-
E1 cells. Data were expressed as a percentage of control. The control
value for collagen content was 12.8 ± 0.305 nmole/mg. ∗P<0.05
compared with control.
3.2. Eﬀect of Magnolol on the Intracellular Glutathione
Content of MC3T3-E1 Cells. Glutathione content reﬂects the
amount of substrate available to act as antioxidant. The
level of glutathione after magnolol exposure for 48h was
signiﬁcantly increased at the concentration of 0.1 and 1μM
as compared with control, indicating that magnolol-induced
enhancements of osteoblast function are associated with an
increase in glutathione (Figure 5).
3.3. Eﬀect of Magnolol on RANKL Production of MC3T3-E1
CellsinthePresenceofAntimycinA. Inordertofurtherdeter-
minetheregulatorofosteoclastdiﬀerentiationinosteoblasts,
we examined the production of RANKL in the osteoblastic
MC3T3-E1 cells. When 70μM antimycin A was added
to cells, the production of RANKL increased signiﬁcantly
(Figure 6). However, antimycin A-induced RANKL produc-
tion was signiﬁcantly inhibited by treatment of magnolol
(0.01∼1μM).
3.4. Eﬀe c to fM a g n o l o lo nA n t i m y c i nA - I n d u c e dT N F - α and
IL-6 Production in MC3T3-E1 Cells. TNF-α and IL-6 have
been demonstrated to increase osteoclastic activity. Thus, we
also investigated whether magnolol modulates antimycin A-
induced production of TNF-α and IL-6 (Figure 7). When
70μM antimycin A was added to cells, production of TNF-
α and IL-6 increased signiﬁcantly. However, antimycin A-
induced TNF-α and IL-6 productions were signiﬁcantly
inhibited by treatment of magnolol at 0.01∼1μMa n d0 . 1 ∼
1μM, respectively.
4. Discussion
The osteoblast phenotypes are acquired in two stages. In
the ﬁrst stage, the matrix matures and speciﬁc proteins
associated with the bone cell phenotype, such as collagen
and ALP, are detected. In the second stage, matrix becomes
mineralized by calcium deposition. As a result, layers of
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Figure 6: Eﬀect of magnolol on antimycin A-induced RANKL pro-
duction of MC3T3-E1 cells. Eﬀect of magnolol on the production
of RANKL in the presence of antimycin A. Osteoblasts were pre-
incubated with magnolol before treatment with 70μM antimycin A
for48h.Datawereexpressedasapercentage ofcontrol.Thecontrol
value for RANKL was 3.378 ± 0.074ng/mg. ∗P<0.05, control
versus antimycin A; #P<0.05, antimycin A versus magnolol.
spongy bone are formed around the original cartilage. Later
in development, spaces among the spongy bone are ﬁlled
with bone matrix and become compact bone [17]. Hence,
collagen content and ALP activity, an early diﬀerentiation
marker, and cellular calcium content, a late marker of
diﬀerentiation, were examined to investigate the eﬀects
of magnolol on the diﬀerentiation of osteoblast cells. In
this study, it was found that magnolol markedly increased
osteoblastgrowthanddiﬀerentiationinosteoblasticMC3T3-
E1 cells. The ﬁndings of the present study supported our
hypothesis that magnolol increases the osteogenic eﬀect in
osteoblastic MC3T3-E1 cells and these stimulated osteogenic
eﬀects are mediated by increasing osteoblast proliferation
and diﬀerentiation. Findings from this study show that
magnolol increased osteoblast proliferation during the early
osteoblast proliferation phase. During the early proliferation
period, osteoblasts synthesize and secrete cell-growth pro-
teins such as TGF-β or IGF [18] and collagen, which is the
most abundant protein in extracellular matrix accounting
for matrix maturation [19]. Therefore, we suggest that
increased osteoblast proliferation by magnolol indicates an
anabolic eﬀect on the bone matrix formation by stimulating
osteoblastcellgrowthrateandbyincreasingcollagenouspro-
teinsynthesiswhichisacriticalfactorformatrixmaturation.
Oxidative stress [20] and changes in the bone microen-
vironment composition with aging [21] may play an
important role in the pathogenesis of postmenopausal
osteoporosis by impairing osteoprogenitor cell recruitment
and diﬀerentiation. Jiang et al. [22] studied in vitro the
characteristics of alveolar osteoblasts from elderly women
a n dr e v e a l e dd i ﬀerences in proliferative capacity and bone
formation functions, which dropped with aging. In this
context, an important correlation has been shown between
oxidative stress and postmenopausal bone loss occurrence
during aging. Maggio et al. [23] reported that antioxidantMediators of Inﬂammation 5
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Figure 7: Eﬀect of magnolol on antimycin A-induced cytokines production of MC3T3-E1 cells. Osteoblasts were preincubated with
magnololbeforetreatmentwith70μMantimycinAfor48h.Datawereexpressedasapercentageofcontrol.ThecontrolvaluesforTNF-α(a)
and IL-6 (b) were 0.228 ± 0.006ng/mg and 0.655 ± 0.033ng/mg, respectively. ∗P<0.05, control versus antimycin A; #P<0.05, antimycin
A versus magnolol.
defenses are markedly decreased in plasma of osteoporotic
women. In agreement, Altindag et al. [24] associated this
imbalance between oxidant and antioxidant status in post-
menopausal osteoporosis with increase of osteoclastic activ-
ityanddecreasedosteoblasticactivity.Reducedglutathioneis
considered one of the most important intracellular reducer
agents. This tripeptide is involved in the protection against
cytotoxicity electrophilic agents and metabolites, and it is
also involved with the regulation of the eﬀects of oxidative
stress on the cells, maintaining, in this way, the intracel-
lular redox balance [25]. Glutathione is considered to be
responsible for reactivation of some proteins after suﬀering
oxidative stress [26]. In the presence of glutathione, the
sulfenicderivativecanbeconvertedinamorestableproduct,
preventing further oxidation [27]. In the present study, the
levelofglutathioneaftermagnololexposurewassigniﬁcantly
increased. Our result shows that the enhancement of antioxi-
dantsbymagnololmayberelatedwiththeincreasedfunction
of osteoblasts.
Apart from having an eﬀect on bone formation, osteo-
blasts are also coupled with osteoclasts through the release
of various cytokines, including RANKL [28]. Most proos-
teoclastogenic cytokines act primarily through osteoblasts
to alter levels of RANKL. RANKL is a protein expressed
on the osteoblast cell membrane that binds to its cognate
receptorRANK,whichispresentontheosteoclastprogenitor
membrane. The binding of RANKL to RANK activates
nuclear factor-κB and c-jun N-terminal protein kinase,
which is associated with osteoclastic diﬀerentiation and
activation [29]. Oxidative stress plays an important role
in the destruction of bone cells during the development
of osteoporosis. Impaired mitochondrial function can lead
to increased ROS generation and may increase oxidative
stress if the antioxidant defense mechanisms of the cells
are overwhelmed [30]. Increased oxidative stress caused
by mitochondrial dysfunction is considered the causal link
between elevated ROS and the major biochemical pathways
postulated to be involved in the pathogenesis of senile
disorders [31]. Antimycin A is an inhibitor of mitochondrial
electron transport via its binding to complex III [32]. In
this study, magnolol inhibited the production of RANKL
induced by antimycin A in osteoblastic cells. Dong et al.
[33] reported that 3,3 -diindolmethane, one of the natural
compounds formed during the autolysis of glucobrassicin,
eﬀectively inhibited the expression of RANKL in osteoblastic
cells, leading to the blockade of osteoclastogenesis and con-
sequently an alleviation of experimental arthritis. Because
RANKL is also known to induce actin ring formation in
mature osteoclasts, magnolol-induced inhibition of RANKL
release in osteoblastic cells could result in disruption of actin
tings in osteoclasts.
Several family members are produced by bone cells
a n dh a v eb e e ni m p l i c a t e dt ob ei n v o l v e di nr e g u l a t i o no f
bone metabolism. In the present paper, we show that
TNF-α and IL-6 releases induced by antimycin A were
decreased by magnolol. The inhibitory eﬀect on TNF-
α and IL-6 production by magnolol may contribute to
the bone antiresorbing eﬀect of magnolol and possibly
also play a role in the reduction of bone loss seen in
the vicinity of inﬂammatory processes such as rheumatoid
arthritis and periodontal disease. Although the precise and
detailed mechanism of magnolol inhibition remains to be
scrutinized, we propose that magnolol might be useful as a
potential therapeutic medication for attenuating osteoclast
formation and function in the prevention and treatment of
bone diseases such as osteoporosis. That TNF-α can inhibit
osteoblastdiﬀerentiation,andboneformationiswellknown.
Using two models of osteoblast diﬀerentiation, Gilbert et al.
[34] found that TNF-α inhibited cell diﬀerentiation by
downregulating the transcription of Runx2, which regulates
the expression of bone matrix proteins. RUNX2 protein
stability has also been shown to be destabilized by TNF-α6 Mediators of Inﬂammation
[35]. Hughes and Howells [36] treated osteoblasts derived
from fetal rat calvaria with recombinant human IL-6 and
showed that bone nodule formation was inhibited. Fang and
Hahn[37]examinedtheeﬀectsofIL-6inUMR-106–01cells,
a rat osteoblastic osteosarcoma line, and observed that it
suppressed collagen synthesis. IL-6 may have a role in the
osteopenia associated with inﬂammation in vivo. Patients
with inﬂammatory diseases in whom IL-6 levels are highest
may be at increased risk for osteopenia.
In summary, magnolol increased the proliferation of
osteoblasts and stimulated ALP activity and bone matrix
proteins, such as collagen, and these increases trigger
osteoblastic diﬀerentiation (e.g., mineralized nodule forma-
tion). Moreover, our data indicate that magnolol suppresses
the production of the bone-resorbing factors in the presence
of antimycin A, a mitochondrial inhibitor that increases the
generation of ROS. Thus, magnolol may be a good candidate
for the protection of osteoblast dysfunction. These results
may aid in the development of a therapeutic approach of
magnolol in the prevention of osteoporosis.
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